- Long-term
agreement signed with Veterans Healthcare Supply Solutions Inc. to
directly distribute SofPulse devices to Veterans Administration Facilities
and Department of Defense Healthcare Facilities
- Partnership
with SunMED Medical Solutions, one of the premier medical equipment
distributors and claim experts in the U.S., expands Endonovo’s
distribution capabilities and expands ability of providers, facilities and
patients to seek medical insurance reimbursement
- Holds
27 patents and numerous trademarks for several proprietary technologies
and devices
- Agreement
signed with national recognized hospital for use of SofPulse devices for
wound healing and pain management
- Nationwide
network of independent sales representatives and distributors
Endonovo Therapeutics Inc. (OTCQB: ENDV) develops,
manufactures and distributes evolutionary medical devices focused on the rapid
healing of wounds and reduction of pain, edema and inflammation on and in the
human body. These wearable, non-invasive medical devices are designed to
deliver the company’s proprietary, patent protected Electroceutical Therapy
targeting inflammation, cardiovascular diseases, chronic kidney disease and
central nervous system (“CNS”) disorders.
In accord with its mission to transform the field of
medicine through innovation, Endonovo’s bioelectric Electroceutical devices
harness bioelectricity to restore key electrochemical processes that initiate
anti-inflammatory processes and growth factors in the body necessary for
healing to rapidly occur. Endonovo’s current portfolio of commercial-stage
devices address chronic kidney disease, liver disease non-alcoholic
steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and
ischemic stroke.
Flagship Therapy
SofPulse Electroceutical Therapy is an easy-to-place,
non-invasive device that delivers pulsed electromagnetic frequencies to enhance
post-surgical recovery. Used as a stand-alone therapy or integrated into any
treatment protocol, SofPulse’s targeted pulsed electromagnetic
field (tPEMF) transmits gentle pulses to the tissue causing a positive
biological effect to help reduce swelling and accelerate the body’s natural
recovery process. The low levels of electromagnetic fields are completely safe
and are 1000 times lower than those emitted by a mobile phone.
Because SofPulse lessens the pain of post-surgical recovery,
the patient requires far less prescription medications, thereby minimizing or
eliminating the adverse side effects of narcotics and anti-inflammatory
medication. Studies have shown a greater than 2.2-fold reduction in narcotic
use over the first 48 hours post-procedure. Patients with less pain and medication
may move around sooner, which further stimulates the body’s natural response to
healing.
Certifications
Endonovo’s Electroceutical Therapy is cleared by the U.S.
Federal Drug Administration (“FDA”) for the palliative treatment of pain and
post-surgical edema (swelling) and is CE-marked in the European Economic Area
(“EEA”) for the promotion of wound healing and the palliative treatment of pain
and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”)
has also certified Electroceutical Therapy for the treatment of chronic wounds.
Management
Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.
Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.
Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.
Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.
Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.
David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.
Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.
For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates
relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment